Overview

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

Status:
Completed
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
Details
Lead Sponsor:
Bayer
Treatments:
Radium Ra 223 dichloride
Succinylcholine